CATHERINE DARAH JONES PA-C
Prescription History 1093947608
Physician Assistant in Boston, MA

NPI Status: Active since August 14, 2009

Contact Information

75 FRANCIS ST
BOSTON, MA
ZIP 02115
Phone: (508) 562-7346

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CATHERINE DARAH JONES PA-C, an active Physician Assistant specialist practicing in Boston, MA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 111 documented patient claims. Among these therapy options, the most frequently utilized medication is Paxlovid (Eua), which accounts for 31 claims alone.

Medication Index


Cephalexin

Generic Formulation: CephalexinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 99
MA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.4
Peer Average Days Supply295
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $138.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.55

State Avg Cost Per Claim

$9.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Lagevrio (Eua)

Generic Formulation: MolnupiravirSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 130
MA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.2
Peer Average Days Supply86
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 52.9% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $254.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.80

State Avg Cost Per Claim

$9.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Molnupiravir is a product that the FDA is allowing to be given for emergency use to treat COVID-19. It is used by adults 18 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with molnupiravir. Molnupiravir works by preventing the growth of the virus that causes COVID-19. More information about molnupiravir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use. There is limited information about how safe and effective molnupiravir is for treating COVID-19. Study results show that molnupiravir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of molnupiravir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 44
MA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills43.7
Peer Average Days Supply777
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.8% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $29.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.86

State Avg Cost Per Claim

$20.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Oxycodone-Acetaminophen

Generic Formulation: Oxycodone Hcl/AcetaminophenSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 33
MA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills45.2
Peer Average Days Supply1,043
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.6% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.92

State Avg Cost Per Claim

$19.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to help relieve moderate to severe pain. It contains an opioid pain reliever (oxycodone) and a non-opioid pain reliever (acetaminophen). Oxycodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Paxlovid (Eua)

Generic Formulation: Nirmatrelvir/RitonavirSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 155
MA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.6
Peer Average Days Supply119
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.8% more claims than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $287.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.28

State Avg Cost Per Claim

$10.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Prednisone

Generic Formulation: PrednisoneSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 78
MA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills55.1
Peer Average Days Supply1,107
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.9% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.23

State Avg Cost Per Claim

$6.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CATHERINE DARAH JONES PA-C provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.